• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.
CONCLUSIONS: LncRNA-BLACAT1 regulates the expression of Cyclin D1, reduces the malignant phenotype of drug-resistant cells, and increases the sensitivity of lung cancer cells to DDP. PMID: 33015788 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - October 7, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

SiRNA interfering STAT3 enhances DDP sensitivity in cervical cancer cells.
CONCLUSIONS: STAT3 over-expression is associated with DDP resistance in cervical cancer. Decreasing STAT3 can significantly promote the apoptosis of cervical cancer CaSki cells and decrease the DDP resistance. PMID: 30024597 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - July 20, 2018 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

The role of Notch1 genes in lung cancer A594 cells and the impact on chemosensitivity.
CONCLUSIONS: The Notch1 siRNA can effectively inhibit the expression of Notch1 gene, inhibit the proliferation of lung cancer A549 cells and increase the sensitivity to chemotherapeutic drugs. PMID: 28678318 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - July 7, 2017 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of NSCLC cells to cetuximab through inhibition of eukaryotic translation initiation factor 5A2 activation.
CONCLUSIONS: These findings demonstrate that combined treatment with GC7 could enhance cetuximab sensitivity by inhibiting EIF5A2 in NSCLC cells, implying the potential clinical application of GC7 in cetuximab-based chemotherapy for NSCLC patients. PMID: 27097942 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - April 23, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Knockdown of PRAME enhances adriamycin-induced apoptosis in chronic myeloid leukemia cells.
CONCLUSIONS: PRAME is responsible for the inherent low levels of spontaneous apoptosis in K562 cells. The combination of PRAME siRNA with ADR induced more intense apoptosis compared with each single treatment. PRAME siRNA in combination with ADR is well tolerated and shows greater efficacy than either agent alone in mouse xenograft models. PMID: 26744874 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - January 15, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Cyclin I promotes cisplatin resistance via Cdk5 activation in cervical cancer.
CONCLUSIONS: These data suggest that a cyclin I-Cdk5 complex forms a critical antiapoptotic factor in the process of generating cisplatin resistance in cervical cancer. PMID: 26698249 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - December 25, 2015 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Effect and mechanism analysis of siRNA in inhibiting VEGF and its anti-angiogenesis effects in human osteosarcoma bearing rats.
CONCLUSIONS: The growth of tumor tissue in osteosarcoma bearing rats is inhibited in Ad-VEGF-siRNA group, Ad-VEGF-siRNA + neoadjuvant chemotherapy group and Ad-VEGF-siRNA + anti-angiogenesis chemotherapy group. The effect in Ad-VEGF-siRNA + neoadjuvant chemotherapy is more significant than simple biological therapy or Ad-VEGF-siRNA + anti-angiogenesis chemotherapy. PMID: 26636524 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - December 6, 2015 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research